ELANIX BIOTECHNOLOGIES AG
DGAP-News: Elanix Biotechnologies AG / Key word(s): Contract/Corporate Action Berlin, Germany, 29 May, 2018 -- Elanix Biotechnologies AG (FRA: ELN), a developer of tissue regeneration products for chronic and acute wound care and advanced skin care products for dermatological and gynaecological applications, today announced the appointment of Egon Minar to the joint role of Chief Operating Officer (COO) and Chief Financial Officer (CFO), effective immediately. With extensive management experience spanning over four decades, Egon Minar brings valuable leadership to Elanix's executive team during a time of growth. As both COO and CFO, Egon Minar will oversee the company's finances and will be responsible for the day-to-day operations of the organization. "With a successful career spanning over 40 years, Egon Minar brings a wealth of senior operational and financial management experience to Elanix," said Tomas Svoboda, Elanix's Chief Executive Officer (CEO). "We are thrilled to welcome such a steady hand to oversee financial matters and operational management." "I am very excited and proud to join Elanix and to support Tomas and the Elanix management team in further building up a very successful business," commented Egon Minar. "I am strongly convinced by Elanix's significant growth potential based on excellent products and services." Prior to joining Elanix, Egon Minar held CEO roles at Hamburg-based Navigon AG and Nuremberg-based AEG GmbH/Electrolux GmbH. He has also held successive executive positions at Sony in Europe, at Munich-based OWR Rodenstock and latest at Swiss-based Cafina AG. Egon Minar has extensive experience in management consultancy and supervisory board memberships for multiple companies. #### About Elanix Biotechnologies AG Elanix develops and commercializes tissue regeneration products for chronic and acute wound care as well as advanced skin care for dermatological and gynecological applications. Additionally, Elanix provides services in cell therapy and related technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells. Elanix has registered headquarters in Berlin, Germany, with offices in Wiesbaden, Germany and Nyon, Switzerland. It is listed in the Regulated Market on the Frankfurt Stock Exchange under the symbol ELN.F. For more information and updates, visit www.elanixbiotechnologies.com. Follow us on Twitter @elanix_biotech Contact: Elanix Biotechnologies AG Magdalena Onyszkiewicz Tel: +41 78 667 3650 investor.relations@elanix-bt.com Disclaimer / Forward-looking statements: This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
29.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | Elanix Biotechnologies AG |
| Kurfürstendamm 32 | |
| 10719 Berlin | |
| Germany | |
| Phone: | +41 22 363 66 40 |
| Fax: | +41 22 363 66 41 |
| E-mail: | info@elanix-bt.com |
| Internet: | www.elanixbiotechnologies.com |
| ISIN: | DE000A0WMJQ4 |
| WKN: | A0WMJQ |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf |
| End of News | DGAP News Service |
690147 29.05.2018
